Home

RegeneRx Pipeline

RegeneRx is a publicly traded, clinical-stage, biopharmaceutical company engaged in the design, research and development of novel peptides targeted at diseases with unmet medical needs. RegeneRx’s mission is to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology.

RegeneRx acquired the rights to a novel peptide from the NIH in 1999. This intellectual property for Thymosin Beta 4 (Tβ4) allowed the company to direct its focus on tissue protection and repair in multiple disease indications.

Learn More

Letter to Stockholders December 21, 2020 Letter to Stockholders December 21, 2020

August 19, 2020 Update on ARISE-3 Dry Eye Trial

May 27, 2020 Advisory: Reclassification of Thymosin Beta 4 from New Drug Entity to Biologic


Latest News
Feb 24, 2021

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage biopharmaceutical company focused on tissue protection, repair and regeneration, announced that the...

Jan 26, 2021

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, is addressing rumors...

More >

Subscribe
Sign up below to receive investor news updates from RegeneRx
* Required Fields